Neurocrine Biosciences (NBIX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to -$1.5 billion.
- Neurocrine Biosciences' Enterprise Value fell 3757.09% to -$1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.5 billion, marking a year-over-year decrease of 3757.09%. This contributed to the annual value of -$1.5 billion for FY2025, which is 3757.09% down from last year.
- Neurocrine Biosciences' Enterprise Value amounted to -$1.5 billion in Q4 2025, which was down 3757.09% from -$1.1 billion recorded in Q3 2025.
- Neurocrine Biosciences' 5-year Enterprise Value high stood at -$765.9 million for Q3 2021, and its period low was -$1.5 billion during Q4 2025.
- Moreover, its 4-year median value for Enterprise Value was -$1.0 billion (2024), whereas its average is -$1.0 billion.
- Data for Neurocrine Biosciences' Enterprise Value shows a peak YoY increase of 2206.34% (in 2025) and a maximum YoY decrease of 3757.09% (in 2025) over the last 5 years.
- Over the past 4 years, Neurocrine Biosciences' Enterprise Value (Quarter) stood at -$765.9 million in 2021, then plummeted by 35.74% to -$1.0 billion in 2023, then fell by 3.51% to -$1.1 billion in 2024, then plummeted by 37.57% to -$1.5 billion in 2025.
- Its Enterprise Value stands at -$1.5 billion for Q4 2025, versus -$1.1 billion for Q3 2025 and -$975.6 million for Q2 2025.